GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CSL300

CSL300

Company
CSL Behring
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for CSL300 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04494724

    Clazakizumab vs. Placebo - COVID-19 Infection

    Not yet reported The Methodist Hospital Research Institute 60 participants Est. completion 2021-07-31 1 site Stand-alone
    Other conditions: COVID-19 Infection
    View official trial listing →
  • Recruiting NCT NCT05485961

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Not yet reported, Not yet reported CSL Behring 3110 participants Est. completion 2029-05-22 566 sites Stand-alone
    Other conditions: End Stage Kidney Disease
    View official trial listing →
  • Recruiting NCT NCT07619820

    A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

    Not yet reported CSL Behring 24 participants Est. completion 2027-11-30 1 site Stand-alone
    Other conditions: End Stage Kidney Disease (ESKD)
    View official trial listing →
  • Completed NCT NCT00866970

    Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

    Not yet reported CSL Behring 124 participants Est. completion 2009-12 43 sites
    Other conditions: NSCLC, Fatigue, Cachexia
    View official trial listing →
  • Completed NCT NCT00867516

    Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis

    Not yet reported CSL Behring 127 participants Est. completion 2009-12 26 sites
    Other conditions: Arthritis, Rheumatoid
    View official trial listing →
  • Completed NCT NCT01373151

    Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

    Not yet reported CSL Behring 418 participants Est. completion 2015-06 100 sites
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Terminated NCT NCT01403064

    Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

    Not yet reported CSL Behring 76 participants Est. completion 2014-03 31 sites
    Other conditions: Oral Mucositis
    View official trial listing →
  • Completed NCT NCT01490450

    Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

    Not yet reported CSL Behring 165 participants Est. completion 2015-06 49 sites
    Other conditions: Arthritis, Psoriatic
    View official trial listing →
  • Terminated NCT NCT01530256

    Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

    Not yet reported, Not yet reported CSL Behring 3 participants Est. completion 2013-03 5 sites
    Other conditions: Acute GvHD
    View official trial listing →
  • Terminated NCT NCT01545050

    Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

    Not yet reported CSL Behring 72 participants Est. completion 2013-12 56 sites Stand-alone
    Other conditions: Crohn's Disease
    View official trial listing →
  • Completed NCT NCT02015520

    Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

    Not yet reported CSL Behring 143 participants Est. completion 2015-06 55 sites Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT03380377

    Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant

    Not yet reported, Not yet reported Stanley Jordan, MD 10 participants Est. completion 2024-04-16 1 site Stand-alone
    Other conditions: Antibody-mediated Rejection, Kidney Transplant; Complications, Transplant Glomerulopathy, Transplant Glomerulopathy - Late Form, Transplant Glomerulopathy - Early Form, Kidney Transplant Rejection
    View official trial listing →
  • Active, not recruiting NCT NCT03380962

    Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

    Not yet reported, Not yet reported Stanley Jordan, MD 20 participants Est. completion 2025-08-30 1 site Stand-alone
    Other conditions: Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
    View official trial listing →
  • Completed NCT NCT03444103

    A Pilot Trial of Clazakizumab in Late ABMR

    Not yet reported Medical University of Vienna 20 participants Est. completion 2020-06-30 2 sites
    Other conditions: Antibody-mediated Rejection
    View official trial listing →
  • Terminated NCT NCT03744910

    Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

    Not yet reported CSL Behring 194 participants Est. completion 2024-04-08 142 sites
    Other conditions: Antibody-mediated Rejection
    View official trial listing →
  • Completed NCT NCT04129931

    PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

    Not yet reported University of North Carolina, Chapel Hill 950 participants Est. completion 2025-03-19 29 sites Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Completed NCT NCT04343989

    A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

    Not yet reported NYU Langone Health 178 participants Est. completion 2021-03-12 3 sites Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT04348500

    Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

    Not yet reported Cedars-Sinai Medical Center 17 participants Est. completion 2020-09-30 1 site
    Other conditions: COVID-19
    View official trial listing →
  • Terminated NCT NCT04381052

    Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

    Not yet reported Columbia University 1 participants Est. completion 2021-04-01 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Completed NCT NCT05727384

    Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

    Not yet reported Anne B. Newman 29 participants Est. completion 2026-05-26 1 site Stand-alone
    Other conditions: Inflammation, Frailty
    View official trial listing →
  • Not yet recruiting NCT NCT07783802

    A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

    Not yet reported Eli Lilly and Company 120 participants Est. completion 2027-10 47 sites Stand-alone
    Cardiovascular diseaseType 2 diabetes Other conditions: Atherosclerosis, Obesity, Hypertension, Renal Insufficiency, Chronic
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: CSL300, Clazakizumab

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.